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IS PRIOR COMMUNITY ANTIBIOTIC 
TREATMENT OF PATIENTS HOSPITALISED 
WITH LOWER RESPIRATORY TRACT 
INFECTION ASSOCIATED WITH REDUCED IN-
HOSPITAL MORTALITY AND LENGTH OF STAY?
Steinke D, Donnan P, MacDonald T, Davey P
Medicines Monitoring Unit, Ninewells Hospital, Dundee, 
Scotland
BACKGROUND: A previous study (Davey et al, Value
in Health 1999, 2:333–341) suggested that prior commu-
nity antibiotic therapy is associated with reduced in-hos-
pital mortality. OBJECTIVES: To confirm the original
finding in a larger study and to test the hypothesis that
patients who received prior antibiotic treatment would
also have lower hospital length of stay. METHODS: Pa-
tients with hospital discharge codes including lower res-
piratory infections (LRTI) or chronic obstructive airways
disease (COAD) were identified at three acute hospitals
from ICD9 codes in the Scottish Morbidity Records
(SMR) for 1993 to 1995. Patients with episodes starting
48h after admission were excluded because they were
likely to have nosocomial pneumonia. Prior antibiotic
treatment was defined as any treatment in the 28 days be-
fore hospitalization. RESULTS: There were 1285 pa-
tients with LRTI alone and 1603 with COAD of whom
366 also had LRTI. Antibiotic treatment occurred before
hospitalization in 35% of patients with LRTI alone and
41% of patients with COAD. Patients with LRTI alone
who received community antibiotics were less likely to
die in the 50 days after admission: relative risk 0.73
(95% CI 0.61–0.87) unadjusted and 0.83 (0.69–1.00)
adjusted for age, sex and social deprivation. There was
no difference in 50 day mortality between COAD pa-
tients who did or did not receive community antibiotics.
Age was the only variable that was significantly associated
with length of stay in the LRTI patients. Length of stay
was not different for patients who received community an-
tibiotics, either in the entire cohort (P  0.25) or in the
832 patients who were discharged alive (P  0.81). CON-
CLUSION: This study confirmed that community antibi-
otic treatment is associated with reduced 50 day mortality
for patients admitted with LRTI, but not COAD. How-
ever, there was no significant association between commu-
nity antibiotic treatment and length of hospital stay.
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PHARMACOGENOMICS: EVALUATING THE 
ECONOMIC IMPACT
Veenstra DL, Higashi MK
University of Washington, Seattle, WA, USA
OBJECTIVE: Pharmacogenomics, the individualization
of drug therapy based on genetic information, promises
to change the clinical use of therapeutics and influence
the drug development process, however the potential
clinical and economic outcomes of pharmacogenomics is
not clear. Our objective is to develop a framework for
evaluating the cost-effectiveness of genetic-guided drug
therapy. METHODS: We reviewed examples of currently
practiced non-genetically based individualization of drug
therapy. These examples were classified into two catego-
ries: dose modification and drug selection. The costs, re-
sponse characteristics, and implementation strategy for
the tests were evaluated. We also evaluated the therapeu-
tics and diseases for which these tests were used to deter-
mine which characteristics led to the implementation of
individualized drug therapy. We then developed a frame-
work for evaluating the cost-effectiveness of pharmaco-
genomics and applied it to examples of currently debated
pharmacogenomic strategies. RESULTS: Drug monitor-
ing is typically employed only for drugs with a narrow
therapeutic index, whereas drug selection is often em-
ployed with the use of antimicrobials, where drug effec-
tiveness is highly dependent on diagnostic information.
The economic and, importantly, the time cost are impor-
tant determinates of the usefulness of testing procedures.
The prevalence of polymorphisms, the penetrance of dis-
ease-related genes, and the magnitude of relative risk will
also have a significant impact on the usefulness of genetic
diagnostics. We found that some commonly cited exam-
ples of potential applications of pharmacogenomics do not
fulfill these criteria. Our analysis suggests that drug-gene
interactions such as warfarin-CYP2C9, 6-mercaptopu-
rine-TPMT, and COX-II inhibitors-Familial Adenomatous
Polyposis (FAP) have the potential to produce cost-effec-
tive results. CONCLUSIONS: The use of pharmacoge-
nomics to improve the cost-effectiveness of pharmaceuti-
cals requires careful evaluation and will not be useful in
all cases.
CEB2
COST-EFFECTIVENESS OF MENINGOCOCCAL 
VACCINE IN THE UK
Brown RE1, Sorensen S1, Batista C1, Nuijten M2
1MEDTAP International Inc., Bethesda, MD, USA; 2MEDTAP 
International Inc., Amsterdam, The Netherlands
OBJECTIVE: Conduct cost-effectiveness analysis of vac-
cinating children in the UK under one year or aged 1 to 4
years against meningococcal serotype C disease. METH-
ODS: A model was developed to estimate the number of
cases and deaths avoided and years of life gained over a
lifetime. The incidence of disease was based upon menin-
gococcal disease reported in the UK and assumes 34% is
serotype C. The vaccine efficacy was assumed to be 90%
based on clinical evidence. Estimated direct medical re-
sources consumed in the acute management of meningo-
coccal disease, acute, and short-term sequelae were ob-
tained from physician opinion. The costs associated with
the management of hearing loss, cerebral palsy, seizures,
and mental retardation over the long term were obtained
